We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

24 hedge funds and large institutions have $36.9M invested in Milestone Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

117% more capital invested

Capital invested by funds: $17M → $36.9M (+$19.9M)

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

26% more funds holding

Funds holding: 19 → 24 (+5)

1.97% more ownership

Funds ownership: 37.64% → 39.6% (+2%)

Holders
24
Holders Change
+5
Holders Change %
+26.32%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
3
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$1.78M
2
KPF
K2 Principal Fund
Ontario, Canada
+$547K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$179K
4
BFM
Boothbay Fund Management
New York
+$154K
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$129K

Top Sellers

1
GTC
Ghost Tree Capital
New York
-$384K
2
Millennium Management
Millennium Management
New York
-$353K
3
SFM
Sphera Funds Management
Israel
-$125K
4
PM
Prosight Management
Texas
-$77K
5
BlackRock
BlackRock
New York
-$22.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
26
Sphera Funds Management
Israel
– -$125K -67,992 Closed
PM
27
Prosight Management
Texas
– -$77K -41,592 Closed
Renaissance Technologies
28
Renaissance Technologies
New York
– -$19K -10,242 Closed
CFA
29
Carroll Financial Associates
North Carolina
– +$129 +40 New
1
2

MIST Hedge Fund Activity: Q2 2020 in Review

24 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2020, worth a combined $36.9M — up 117% from $17M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new MIST positions and 6 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.78M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $384K sold.

  • 24 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2020, up from 19 in Q1 2020.
  • Funds reported $36.9M of Milestone Pharmaceuticals stock for Q2 2020, up 117% quarter-over-quarter.
  • 11 funds opened new Milestone Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of +5 holders.
  • The largest Milestone Pharmaceuticals buyer in Q2 2020 was Morgan Stanley, an estimated $1.78M added.
  • The largest Milestone Pharmaceuticals seller in Q2 2020 was Ghost Tree Capital, an estimated $384K sold.

Based on aggregated 13F filings for Q2 2020.